Exploring Opportunities to Reform Antimicrobial Payment and Post Market Incentives

Marriott Metro Center, Washington, DC
January 16, 2020 • 10:00 am – 4:30 pm

Speaker Biographies

**Michael Chang** is a venture capital investor at Adjuvant Capital, a life sciences investment fund focused on financing the development of novel drugs, vaccines and other technologies that address major global health challenges in infectious disease and maternal and child health. Adjuvant is sponsored by a consortium of global health and development organizations including the Bill & Melinda Gates Foundation (BMGF) and the International Finance Corporation (IFC). Prior to joining Adjuvant, Michael spent three years at BMGF, where he worked with its Global Health Division and Strategic Investment Fund to structure investments into biotech companies, leading academic centers, and other non-profit organizations that have the goal of catalyzing technological innovation in global health. Before joining BMGF, Michael spent several years covering the specialty pharmaceuticals sector as an equity research analyst at Piper Jaffray in New York. Michael started his career in the investment banking practice at Stifel where he focused on mergers and acquisitions advising. He earned a BA in International Relations from Johns Hopkins University.

**Nick Crabb** had a 20 year career in analytical science, process technology and general management in the chemical, pharmaceutical and contract laboratory industries prior to joining NICE in 2010 as the associate director responsible for establishing and managing the Diagnostics Assessment Programme. In 2014 Nick was appointed to his current role where he oversees NICE Scientific Advice, the Science Policy and Research programme and NICE’s input to the European Network for Health Technology Assessment (EUnetHTA). Nick has broad scientific and policy interests relating to the evaluation of technologies and interventions to support the development of clinical, public health and social care guidance. His experience includes consideration of HTA issues arising from the availability of novel new products such as cell and gene therapies and work on methods issues relating to the evaluation of antimicrobials.

**Michael Craig**, Senior Advisor for CDC’s Antibiotic Resistance Coordination and Strategy Unit, leads the coordination of CDC’s $170 million cross-cutting antibiotic resistance portfolio by developing and guiding CDC’s strategic direction to address national goals to combat antibiotic resistance. He also works closely with leadership within the U.S. Department of Health and Human Services (HHS) and with the President’s Advisory Committee for Combatting Antibiotic-Resistant Bacteria (PACCARB) to align public health activities related to antibiotic resistance across multiple federal agencies.
Suzanne Edwards recently joined the Global AMR R&D Hub as an economist, working to shape the Hub’s approach to incentives. Previously, she was a freelance researcher and analyst contributing – among other things – to the EU’s Innovative Medicine Initiative DRIVE-AB project, the German Government’s 2015 GUARD report and the London School of Economics’ 2009 landmark study on antimicrobial resistance incentives in support of the EU’s Swedish presidency. Prior to specialising in pharmaceutical innovation and market failures, she was the first Head of Research at the Access to Medicine Foundation. Suzanne began her career working for the pharmaceutical industry before spending some time managing humanitarian response projects in conflict settings. She holds degrees in pharmacology and health economics and is currently working towards her doctoral thesis.

Robert Horne is the founder of Forest Hill Consulting based in Washington, D.C. Robert advises complex health care alliances on health policy and provides federal advocacy and strategic consulting services to provider organizations, pharmaceutical and device companies, health IT vendors, consumer and patient organizations, and payers. Robert has extensive expertise in a range of health policy areas, including FDA regulatory policy, CMS and payment and delivery transformation, digital health, public health, and health care reform. Robert spent 10 years on Capitol Hill as professional staff on the House Energy and Commerce Committee under Chairman Fred Upton, and as senior health policy adviser to Congressman Phil Gingrey. During his tenure he helped author numerous laws affecting the Medicare program, FDA, and NIH, including the 2015 law that modernized the Physician Payment system under the Medicare program (known as MACRA), the 21st Century Cures Act, and the 2012 law creating incentives to spur antibiotic drug development. Before that, Robert served as the staff director for the Health Committee in the Ohio House of Representatives where he helped establish and execute the agenda of Chairman Greg Jolivette. Prior to founding Forest Hill Consulting, Robert served as a principal in the Washington D.C. offices of Leavitt Partners, and as Executive Director of the Health IT Now Coalition.

Brenda Huneycutt is a director of FasterCures, a center of the Milken Institute. She leads a portfolio of projects focused on creating a high-functioning biomedical ecosystem that works for all patients. Her work includes developing a biomedical ecosystem performance scorecard, creating tools to increase representation of patient perspectives in healthcare decision-making, driving transparency in medical product development, and accelerating the development of new antibiotics. Prior to joining FasterCures, Huneycutt was vice president, regulatory strategy and FDA policy at Avalere Health, advising health-care clients on topics such as patient engagement in drug development, compassionate use/expanded access to investigational products, regulatory exclusivities, the Food and Drug Administration’s orphan drug and expedited programs, and the use of real-world evidence in regulatory decision-making. Prior to that, Huneycutt practiced as a patent lawyer working on generic pharmaceutical and biotech patent litigation. Huneycutt started out as a research scientist, primarily studying cell division and cell cycle control in yeast model systems. Huneycutt is a fellow with the Coalition for Epidemic Preparedness Innovations, working on challenges related to developing vaccines against diseases with epidemic potential. Huneycutt holds a PhD in molecular biology from the University of Colorado at Boulder, a JD from the George Washington University School of Law, and an MPH from the Johns Hopkins University Bloomberg School of Public Health.
Jeremy Knox leads the Wellcome Trust’s expanding policy and advocacy programme on antimicrobial resistance, as a key part of the organisation’s five-year, £175m commitment to support the global response to drug-resistant infections through integrated research and policy activities. He joined Wellcome in July 2017 after eight years working in government at the UK Department for Health. During this time, Jeremy worked in public and global health roles, including a two year secondment from 2014 to 2016 to be deputy head of the small team working on Lord Jim O’Neill’s Review on Antimicrobial Resistance. Having originally studied economics at the University of Nottingham, Jeremy also holds a master’s degree in Health Policy from Imperial College, London.

Mark McClellan is Director and Robert J. Margolis, M.D., Professor of Business, Medicine and Health Policy at the Margolis Center for Health Policy at Duke University. He is a physician-economist who focuses on quality and value in health care, including payment reform, real-world evidence and more effective drug and device innovation. He is former administrator of the Centers for Medicare & Medicaid Services and former commissioner of the U.S. Food and Drug Administration, where he developed and implemented major reforms in health policy. He is an independent director on the boards of Johnson & Johnson, Cigna, and Alignment Health Care and is co-chair of the Accountable Care Learning Collaborative and the Guiding Committee for the Health Care Payment Learning and Action Network.

Karla M. Miller is the Vice President of Pharmacy Services & Clinical Therapeutics for Hospital Corporation of America (HCA Healthcare) in Nashville, Tennessee. In her current position she oversees the medication management and Pharmacy Services for the Hospitals, Ambulatory Surgery Centers, and Physician Practices in HCA. She oversees the Clinical Pharmacy Program, Antimicrobial Management Program, Barcode Medication Administration, Medication Diversion Prevention, as well other clinical and medication management programs. She is co-executive sponsor for the clinical pharmacy surveillance software that was implemented to prevent life-threatening medication errors, improve patient outcomes and reduce drug waste. Dr. Miller is the Pharmacy Task Force Chair for the Federation of American Hospitals. Prior to her current position she served in the Corporate Medication Use and Safety Position. Her interest in safety started with her work in Safety as a Psychiatric Clinical Specialist at Centennial Medical Center in Nashville, TN. She is a board certified psychiatric pharmacist. Dr. Miller is also an Assistant Professor at the University of Tennessee College of Pharmacy. She received her Doctor of Pharmacy degree from West Virginia University. She completed a pharmacy practice residency at Johns Hopkins Hospital in Baltimore, Maryland, and a two-year fellowship in neuropsychiatry at The Ohio State University in Columbus, Ohio.

Soumi Saha serves as the Senior Director of Advocacy at Premier Inc. where she is responsible for influencing legislative and regulatory proposals that support a competitive drug marketplace and lead the transformation to high-quality, cost-effective healthcare. Soumi previously held positions as the Director of Pharmacy & Regulatory Affairs at the Academy of Managed Care Pharmacy (AMCP) and the Director of National Pharmacy Controls at Kaiser Permanente. Soumi has a Doctor of Pharmacy (PharmD) from the University of Maryland School of Pharmacy and a Juris Doctor (JD) with a concentration in Health Law from the University of Maryland School of Law.
Kevin Outterson teaches health care law at Boston University, where he co-directs the Health Law Program. He serves as the Executive Director and Principal Investigator for CARB-X, a $500M international public-private partnership to accelerate global antibacterial innovation. Key partners in CARB-X include the US Government (BARDA & NIAID), the Wellcome Trust, the UK Government (GAMRIF, DHSC), the German Federal Ministry of Education and Research, and the Bill & Melinda Gates Foundation. Professor Outterson’s research work focuses on the law and economics of antimicrobial resistance (available at Google Scholar). He served as a senior author on many key research reports on antibiotic innovation, including Chatham House, ERG, DRIVE-AB, and the Lancet Commission. Professor Outterson was given the 2015 Leadership Award by the Alliance for the Prudent Use of Antibiotics for his research and advocacy work. He has testified before Congress, Parliamentary working groups, WHO, and several state legislatures. Since August 2016, he leads CARB-X, the world’s largest and most innovative antibiotic accelerator.

Samuel Peasah is a senior advisor at the Center for Value-based Pharmacy Initiatives within the Center for High Value HealthCare, UPMC Insurance Services Division, Pittsburgh PA. Dr. Peasah is a registered pharmacist, trained additionally as a health services researcher at University of Florida and was a health economics research fellow at the CDC. Until recently, he was faculty member and director for the Center for Outcomes Research and Education at Mercer University College of Pharmacy. His research interest is in health economics and impact of policy changes & interventions on health outcomes. He is currently involved in value-based contracting assessment and outcomes evaluation at UPMC. Dr. Peasah is married with three children and enjoys tennis.

Kevin Ronneberg is Vice President, Health Initiatives and Medical Director for HealthPartners, a health solutions organization providing care, coverage and research. He is responsible for ensuring market needs of employers and consumers are reflected into the organizations work and policy forums and connecting purchaser and care delivery perspectives in designing health solutions that improve health and well-being, affordability and experience. He has served as a committee member and advisor for several regional and national organizations including the National Academies of Science, Engineering and Medicine and the National Business Group on Health. Dr. Ronneberg has held executive leadership roles in health plans, pharmacy, retail and care delivery organizations. Prior to HealthPartners, he led Target’s pharmacy and clinics professional services and health system partnerships. He is a graduate of the University of Minnesota Medical School and is board certified in family medicine.

Monika Schneider is a Managing Associate within the biomedical innovation team at the Duke-Margolis Center for Health Policy. Her work focuses on incentive mechanisms and payment reform models that could encourage development in areas of medical unmet need. Monika's portfolio includes antimicrobial products, Alzheimer's disease drugs, neglected diseases, and oncology products. Prior to Duke-Margolis, Monika was a Science Policy Analyst at the American Association of Immunologists, where she focused on policies affecting the biomedical research community. Monika is an immunologist by training, and previous experimental research included the host immune response to viral infection and the role of the immune system in cancer development.
Susan Van Meter is executive director of AdvaMedDx. AdvaMedDx represents manufacturers of in vitro diagnostic (IVD) tests and technologies. AdvaMedDx member company innovations allow early detection of disease, facilitate evidence-based medicine, improve patient health and health care, and enable personalized medicine, while often lowering overall health care costs. AdvaMedDx is the only advocacy organization exclusively addressing policy issues facing diagnostics manufacturers in the U.S. and around the world. AdvaMedDx operates as a division of AdvaMed, the Advanced Medical Technology Association. AdvaMed is the world’s largest medical technology association, with over 400 member companies that develop medical devices, diagnostic tools, and health information systems. Prior to joining AdvaMedDx in 2018, Ms. Van Meter served as senior vice president at the Healthcare Association of New York State (HANYS), focused on hospital and health system policy, payment, quality and health information technology priorities. Ms. Van Meter has an undergraduate degree in Political Science and French from Villanova University and a MA in Political Science from Boston University.